Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

StageZero Life Sciences

DB:61N
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
61N
DB
CA$21M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. The last earnings update was 144 days ago. More info.


Add to Portfolio Compare Print
  • StageZero Life Sciences has significant price volatility in the past 3 months.
61N Share Price and Events
7 Day Returns
119.6%
DB:61N
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-43.9%
DB:61N
-13.2%
DE Biotechs
-20.9%
DE Market
61N Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
StageZero Life Sciences (61N) 119.6% 102% 119.6% -43.9% -78.7% -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 61N underperformed the Biotechs industry which returned -13.2% over the past year.
  • 61N underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
61N
Industry
5yr Volatility vs Market

Value

 Is StageZero Life Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether StageZero Life Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as StageZero Life Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for StageZero Life Sciences. This is due to cash flow or dividend data being unavailable. The share price is €0.0505.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for StageZero Life Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are StageZero Life Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:61N PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.02
TSX:SZLS Share Price ** TSX (2020-04-03) in CAD CA$0.07
TSX:SZLS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.708 $0.05
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of StageZero Life Sciences.

DB:61N PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:SZLS Share Price ÷ EPS (both in USD)

= 0.05 ÷ -0.02

-1.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • StageZero Life Sciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • StageZero Life Sciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does StageZero Life Sciences's expected growth come at a high price?
Raw Data
DB:61N PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for StageZero Life Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on StageZero Life Sciences's assets?
Raw Data
DB:61N PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $-0.02
TSX:SZLS Share Price * TSX (2020-04-03) in CAD CA$0.07
TSX:SZLS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.708 $0.05
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:61N PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:SZLS Share Price ÷ Book Value per Share (both in USD)

= 0.05 ÷ -0.02

-2.24x

* Primary Listing of StageZero Life Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • StageZero Life Sciences has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of 61N’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through StageZero Life Sciences's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess StageZero Life Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. StageZero Life Sciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is StageZero Life Sciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as StageZero Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is StageZero Life Sciences expected to grow at an attractive rate?
  • Unable to compare StageZero Life Sciences's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare StageZero Life Sciences's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare StageZero Life Sciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:61N Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:61N Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:61N Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 0 -5 -4
2019-06-30 0 -3 -7
2019-03-31 0 -3 -9
2018-12-31 0 -3 -4
2018-09-30 0 -3 -4
2018-06-30 0 -3 -4
2018-03-31 0 -3 -2
2017-12-31 0 -4 -3
2017-09-30 1 -5 -2
2017-06-30 1 -5 -4
2017-03-31 1 -5 -5
2016-12-31 1 -4 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if StageZero Life Sciences is high growth as no earnings estimate data is available.
  • Unable to determine if StageZero Life Sciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:61N Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from StageZero Life Sciences Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:61N Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.02
2019-06-30 -0.04
2019-03-31 -0.07
2018-12-31 -0.03
2018-09-30 -0.03
2018-06-30 -0.04
2018-03-31 -0.02
2017-12-31 -0.03
2017-09-30 -0.02
2017-06-30 -0.05
2017-03-31 -0.07
2016-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if StageZero Life Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 61N’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. StageZero Life Sciences's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. StageZero Life Sciences's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess StageZero Life Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
StageZero Life Sciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has StageZero Life Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare StageZero Life Sciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • StageZero Life Sciences does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare StageZero Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare StageZero Life Sciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
StageZero Life Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from StageZero Life Sciences Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:61N Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 0.16 -4.39 4.00
2019-06-30 0.23 -7.27 3.35
2019-03-31 0.23 -9.34 3.69
2018-12-31 0.19 -3.94 3.46
2018-09-30 0.17 -4.27 3.68
2018-06-30 0.13 -4.20 4.44
2018-03-31 0.23 -2.02 4.07
2017-12-31 0.41 -2.95 4.33
2017-09-30 0.64 -1.51 3.91
2017-06-30 0.70 -3.68 4.25
2017-03-31 1.11 -4.75 4.39
2016-12-31 1.05 -5.91 3.99
2016-09-30 0.77 -8.48 4.14
2016-06-30 -0.25 -7.93 3.37
2016-03-31 -0.18 -7.70 3.08
2015-12-31 0.33 -6.02 3.18
2015-09-30 0.94 -6.51 3.87
2015-06-30 2.93 -5.62 4.30
2015-03-31 2.70 -6.51 4.37
2014-12-31 2.22 -6.95 4.42
2014-09-30 1.64 -7.23 3.63
2014-06-30 0.67 -9.82 3.99
2014-03-31 0.26 -8.77 3.71
2013-12-31 0.12 -8.85 3.72
2013-09-30 0.15 -7.71 3.61
2013-06-30 0.26 -5.65 3.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if StageZero Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if StageZero Life Sciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if StageZero Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess StageZero Life Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
StageZero Life Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is StageZero Life Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up StageZero Life Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • StageZero Life Sciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • StageZero Life Sciences's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of StageZero Life Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • StageZero Life Sciences has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from StageZero Life Sciences Company Filings, last reported 6 months ago.

DB:61N Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -4.97 2.36 0.41
2019-06-30 -9.56 2.85 0.75
2019-03-31 -10.36 3.40 0.21
2018-12-31 -4.84 3.22 0.11
2018-09-30 -5.17 3.60 0.02
2018-06-30 -4.60 3.56 0.72
2018-03-31 -2.98 2.09 0.01
2017-12-31 -3.02 1.58 0.04
2017-09-30 -3.81 3.51 0.01
2017-06-30 -4.34 3.35 0.06
2017-03-31 -5.14 3.17 0.11
2016-12-31 -4.73 3.02 0.21
2016-09-30 -6.60 2.24 0.03
2016-06-30 -4.98 2.74 0.04
2016-03-31 -3.93 2.30 0.27
2015-12-31 -1.77 1.32 0.52
2015-09-30 -0.03 0.93 0.45
2015-06-30 1.20 0.90 0.45
2015-03-31 2.30 0.00 2.64
2014-12-31 2.16 0.00 2.34
2014-09-30 4.15 0.00 3.94
2014-06-30 -1.71 0.00 0.51
2014-03-31 0.39 0.00 1.14
2013-12-31 1.75 0.26 2.78
2013-09-30 -1.09 4.78 4.94
2013-06-30 1.78 4.46 6.04
  • StageZero Life Sciences has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if StageZero Life Sciences's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • StageZero Life Sciences has less than a year of cash runway based on current free cash flow.
  • StageZero Life Sciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.8% each year.
X
Financial health checks
We assess StageZero Life Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. StageZero Life Sciences has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is StageZero Life Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from StageZero Life Sciences dividends.
If you bought €2,000 of StageZero Life Sciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate StageZero Life Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate StageZero Life Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:61N Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as StageZero Life Sciences has not reported any payouts.
  • Unable to verify if StageZero Life Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of StageZero Life Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as StageZero Life Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess StageZero Life Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can StageZero Life Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. StageZero Life Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of StageZero Life Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James Howard-Tripp
COMPENSATION $404,802
TENURE AS CEO 3.7 years
CEO Bio

Mr. James R. Howard-Tripp has been the Executive Chairman of GeneNews Limited (also known as ChondroGene Ltd.) since July 2013 and has been its Chief Executive Officer since August 08, 2016. Mr. Howard-Tripp serves as Chief Executive Officer at Innovative Diagnostic Laboratory, LLP. He has specialized in the research, development and launch of innovative pharmaceutical products and the growth and development of the companies that research and market them. He served as the President and Chief Executive Officer of Labopharm Inc. from July 2000 to March 2011. He served as the Chairman, Chief Executive Officer and President of Labopharm Europe Ltd. He initially joining Labopharm Inc. as Executive Vice President in March, 2000. From 1996, he held a number of positions with Allelix Biopharmaceuticals Inc., the last position being that of President and Chief Executive Officer of Allelix Neuroscience Inc., which he assumed in March 1998. From 1994 to 1996, he served as Director and then Vice-President of Business Development at Wyeth-Ayerst Canada Inc. Mr. Howard-Tripp has been a Director of GeneNews Limited since 2002. He served as a Director of Labopharm Inc. from 1999 to March 2011.

CEO Compensation
  • James's compensation has increased whilst company is loss making.
  • James's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the StageZero Life Sciences management team in years:

2.6
Average Tenure
  • The tenure for the StageZero Life Sciences management team is about average.
Management Team

James Howard-Tripp

TITLE
Executive Chairman & CEO
COMPENSATION
$405K
TENURE
3.7 yrs

Choong-Chin Liew

TITLE
Co-Founder
COMPENSATION
$230K

Carl Solomon

TITLE
Interim Chief Financial Officer
TENURE
1.5 yrs

Warren Whitehead

TITLE
Chief Accountant
AGE
67
TENURE
1.6 yrs

David Suria

TITLE
Senior Scientist
COMPENSATION
$120K
TENURE
19.2 yrs
Board of Directors Tenure

Average tenure and age of the StageZero Life Sciences board of directors in years:

11.9
Average Tenure
66
Average Age
  • The average tenure for the StageZero Life Sciences board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

James Howard-Tripp

TITLE
Executive Chairman & CEO
COMPENSATION
$405K
TENURE
6.8 yrs

Garth A. MacRae

TITLE
Independent Director
COMPENSATION
$64K
AGE
85
TENURE
19.9 yrs

Bernard Levin

TITLE
Chairman of Colorectal Cancer Clinical Advisory Board
TENURE
12.8 yrs

Harry Glorikian

TITLE
Independent Director
COMPENSATION
$64K
AGE
53
TENURE
11.9 yrs

Rory Riggs

TITLE
Independent Director
COMPENSATION
$102K
AGE
66
TENURE
20.3 yrs

Richard Wender

TITLE
Member of Colorectal Cancer Clinical Advisory Board

David Sidransky

TITLE
Member of Colorectal Cancer Clinical Advisory Board
AGE
59

David Lieberman

TITLE
Member of Colorectal Cancer Clinical Advisory Board

Larry Cohen

TITLE
Member of Colorectal Cancer Clinical Advisory Board
AGE
69
TENURE
11.4 yrs

Khursheed Jeejeebhoy

TITLE
Member of Colorectal Cancer Clinical Advisory Board
TENURE
11.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess StageZero Life Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. StageZero Life Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

StageZero Life Sciences Ltd. focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.

Details
Name: StageZero Life Sciences Ltd.
61N
Exchange: DB
Founded: 1998
CA$13,834,118
324,514,014
Website: http://www.stagezerolifesciences.com
Address: StageZero Life Sciences Ltd.
70 East Beaver Creek Road,
Unit 30,
Richmond Hill,
Ontario, L4B 3B2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX SZLS Common Shares The Toronto Stock Exchange CA CAD 02. Jan 2001
OTCPK GNWS.F Common Shares Pink Sheets LLC US USD 02. Jan 2001
DB 61N Common Shares Deutsche Boerse AG DE EUR 02. Jan 2001
Number of employees
Current staff
Staff numbers
16
StageZero Life Sciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:49
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.